March 12, 2018 / 10:25 AM / 7 months ago

BRIEF-Sienna Biopharmaceuticals Announces First Patient Dosed In Proof-Of-Concept Trial Of Topical By Design JAK Inhibitor SNA-125 For Atopic Dermatitis

March 12 (Reuters) - Sienna Biopharmaceuticals Inc:

* SIENNA BIOPHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN PROOF-OF-CONCEPT TRIAL OF TOPICAL BY DESIGN™ JAK INHIBITOR SNA-125 FOR ATOPIC DERMATITIS

* SIENNA BIOPHARMACEUTICALS INC - ‍TOP-LINE RESULTS FROM STUDY EXPECTED IN Q4 OF 2018​

* SIENNA BIOPHARMACEUTICALS INC - ‍TRIAL TO ENROLL ABOUT 30 PATIENTS WITH ATOPIC DERMATITIS​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below